Boston, MA -- (SBWIRE) -- 09/19/2016 -- Atrial fibrillation (AF) is a disorder of the heart's conduction system. The condition is characterized by an irregular heart rhythm that is either too fast or too slow. During AF, the two upper chambers of the heart (atria) beat out of coordination with the two lower chambers (ventricles) due to disorganized electrical signals. Consequently, the blood doesn't flow as well as it should from the atria to the ventricles, resulting in poor blood supply to the rest of the body. AF symptoms typically include heart palpitations, chest discomfort, shortness of breath, dizziness, and weakness (CDC, 2015; Mayo Clinic, 2016; NHLBI, 2014). However, individuals with AF may be asymptomatic and not even know that they have the condition until it is identified through an electrocardiogram (ECG) test.

Get More Details on this Report and a Full Table of Contents at EpiCast Report: Atrial Fibrillation - Epidemiology Forecast to 2025

In the 8MM, GlobalData epidemiologists forecast that the diagnosed prevalent cases of AF will increase from 9,487,217 cases in 2015 to 11,536,773 cases in 2025, at an Annual Growth Rate (AGR) of 2.16%. The US will have the highest number of diagnosed prevalent cases of AF among the 8MM throughout the forecast period, while Canada will have the lowest. In the 8MM, permanent AF is forecast to be the predominant subtype of AF. In the US, Germany, Spain, the UK, Japan, and Canada, paroxysmal AF is forecast to be the second most predominant subtype, while persistent AF is the second most common subtype in France and Italy.

Scope

-The Atrial fibrillation (AF) EpiCast Report is an overview of the risk factors, comorbidities, and the global and historical trends for AF in the eight major markets (8MM) (US, France, Germany, Italy, Spain, UK, Japan, and Canada). It includes a 10-year epidemiological forecast for the diagnosed prevalent cases of AF based on country-specific studies published in peer-reviewed journals. The diagnosed prevalent cases of AF are segmented by age (at 5-year intervals, starting at age 40 years), sex, and clinical subtypes (paroxysmal, persistent, and permanent AF) in the 8MM.

-The AF epidemiology report is written and developed by Masters- and PhD-level epidemiologists.

-The EpiCast Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 8MM.

Reasons to Get This Report

The AF EpiCast report will allow you to -

-Develop business strategies by understanding the trends shaping and driving the global AF market.

-Quantify patient populations in the global AF market to improve product design, pricing, and launch plans.

-Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for AF therapeutics in each of the markets covered.

About Fast Market Research
Fast Market Research is a leading distributor of market research and business information. Representing the world's top research publishers and analysts, we provide quick and easy access to the best competitive intelligence available. Our unbiased, expert staff is always available to help you find the right research to fit your requirements and your budget. For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 1.800.844.8156.

Browse all Pharmaceuticals research reports at Fast Market Research

You may also be interested in these related reports:

-EpiCast Report: Venous Thromboembolism - Epidemiology Forecast to 2025
-EpiCast Report: Heart Failure - Epidemiology Forecast to 2025
-EpiCast Report: Meningococcal Disease - Epidemiology Forecast to 2025
-EpiCast Report: Idiopathic Pulmonary Fibrosis - Epidemiology Forecast to 2025
-EpiCast Report: Type 2 Diabetes - Epidemiology Forecast to 2025